Cost-effectiveness of Xpert®MTB/RIF in the diagnosis of tuberculosis : pragmatic study.

Simple item page
dc.contributor.authorSilva, Suely Conceição Alves da
dc.contributor.authorVater, Maria Cláudia
dc.contributor.authorRamalho, Daniela Maria de Paula
dc.contributor.authorAlmeida, Isabela Neves de
dc.contributor.authorMiranda, Silvana Spíndola de
dc.contributor.authorKritski, Afrânio Lineu
dc.date.accessioned2023-01-20T17:53:06Z
dc.date.available2023-01-20T17:53:06Z
dc.date.issued2021pt_BR
dc.description.abstractIntroduction: The intensification of research and innovation with the creation of networks of rapid and effective molecular tests as strategies for the end of tuberculosis are essential to avoid late diagnosis and for the eradication of the disease. We aimed to evaluate the cost-effectiveness of Xpert®MTB/RIF (Xpert) in the diagnosis of drug-resistant tuberculosis in reference units, in scenarios with and without subsidies, and the respective cost adjustment for today. Methods: The analyses were performed considering as criterion of effectiveness, negative culture or clinical improvement in the sixth month of follow-up. The comparison was performed using two diagnostic strategies for the drug susceptibility test (DST), BactecTMMGITTM960 System, versus Xpert. The cost effectiveness and incremental cost-effectiveness ratio (ICER) were calculated and dollar-corrected for American inflation (US$ 1.00 = R$ 5,29). Results: Subsidized Xpert had the lowest cost of US$ 33.48 (R$67,52) and the highest incremental average efficiency (13.57), thus being a dominated analysis. After the inflation was calculated, the mean cost was DST-MGIT=US$ 74.85 (R$ 396,73) and Xpert = US$ 37.33 (R$197,86) with subsidies. Conclusions: The Xpert in the diagnosis of TB-DR in these reference units was cost-effective with subsidies. In the absence of a subsidy, Xpert in TB-DR is not characterized as cost effective. This factor reveals the vulnerability of countries dependent on international organizations’ subsidy policies.pt_BR
dc.identifier.citationSILVA, S. C. A. da et al. Cost-effectiveness of Xpert®MTB/RIF in the diagnosis of tuberculosis: pragmatic study. Revista da Sociedade Brasileira de Medicina Tropical, v. 54, artigo e07552020-58, 2021. Disponível em: <https://www.scielo.br/j/rsbmt/a/bYTYxJ6jMrskQjjV5v5TkDR/?lang=en#:~:text=RESULTS%3A,%24197%2C86)%20with%20subsidies.>. Acesso em: 11 out. 2022.pt_BR
dc.identifier.doihttps://doi.org/10.1590/0037-8682-0755-2020pt_BR
dc.identifier.issn1678-9849
dc.identifier.urihttp://www.repositorio.ufop.br/jspui/handle/123456789/16019
dc.language.isoen_USpt_BR
dc.rightsabertopt_BR
dc.rights.licenseThis is an open access article distributed under the terms of the Creative Commons license. Fonte: o PDF do artigo.pt_BR
dc.subjectMultidrug‑resistant tuberculosispt_BR
dc.subjectNew diagnosticspt_BR
dc.subjectInnovationpt_BR
dc.titleCost-effectiveness of Xpert®MTB/RIF in the diagnosis of tuberculosis : pragmatic study.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_CostEffectivenessXpert.pdf
Size:
1.05 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DEACL - Artigos publicados em periódicos